Post-Immunotherapy Axitinib for Patients With Renal Cell Carcinoma

For patients with metastatic renal cell carcinoma (RCC), checkpoint inhibitor therapy is the standard of care. However, if that doesn't work, vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitors can be the next option, but there is no prospective data on the efficacy of these drugs for RCC in this setting. In an attempt to provide evidence for the effectiveness of VEGF-R tyrosine kinase inhibitors for RCC previously treated with immune checkpoint inhibitors, researcher...
Continue reading

Avelumab/Axitinib Approved: Advanced Renal Cell Carcinoma

​The FDA has approved avelumab (Bavencio®, EMD Serono, Inc.) in combination with axitinib (Inlyta®, Pfizer Inc.) as first-line treatment for advanced renal cell carcinoma (RCC). Avelumab is an anti–programmed death ligand 1 (anti–PD-L1) antibody, a type of immune checkpoint inhibitor. Axitinib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), improves tumor infiltration by immune cells. It has antiangiogenic activity, meaning that it prevents tumors from gro...
Continue reading

New First-Line Treatment in Metastatic Renal Cell Carcinoma

Pembrolizumab (Keytruda®, Merck Inc.), previously FDA approved for various cancers, including advanced non-small cell lung cancer, classical Hodgkin lymphoma, and advanced gastric cancer, has now been granted FDA approval to be administered in conjunction with axitinib (Inlyta®, Pfizer Inc.) as first-line treatment for patients with locally advanced or metastatic renal cell carcinoma (RCC). As an immunotherapy drug, pembrolizumab fights cancer by working with the patient's immune system. The dru...
Continue reading

Advanced Renal-Cell Carcinoma: Potential First-Line Treatment

​A phase 3 clinical trial has found that in previously untreated patients with advanced renal-cell carcinoma (RCC), avelumab plus axitinib improves progression-free survival and objective response compared with sunitinib. Sunitinib is an antiangiogenic drug, meaning that it prevents tumors from growing their own blood vessels. It is considered standard of care as a first-line therapy for patients with advanced RCC. However, many patients either have inherent resistance to antiangiogenic drugs or...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.